Non-alcoholic steatohepatitis (NASH) is a disease characterized by fat infiltration and inflammation of the liver and is linked to obesity, metabolic disease and various drug treatments. The prevalence of NASH has increased in parallel with that of metabolic disease, and currently 60 million people in the U.S. are at risk for developing the disease. The current clinical diagnosis for NASH includes liver biopsy, an invasive procedure associated with risk of severe complications.
In collaboration with leading pharmaceutical and academic research teams, Lipomics has identified several mechanism-specific markers of fat accumulation in the liver, two of which are under going validation in clinical trials as plasma based diagnostics for steatosis (LT-07) and NASH (LT-24). These simple blood tests for liver fat accumulation will be used to screen at-risk individuals, enable clinicians to guide early treatment, and is one of many ways that Lipomics is improving disease detection and therapy.
Lipomics has established a leadership position in personalized medicine for metabolic disorders by combining world-class expertise in lipid biology with its technology for quantitative metabolite profiling.
We are developing important diagnostic capabilities for detecting, treating and managing disease with a focus on high-density lipoprotein function, insulin resistance, weight management and inflammation. Lipomics is committed to delivering new pathways to health.
Harvard Scientists collaborated with Lipomics to identify a novel mechanism linking lipid metabolism to insulin action. Lipid profiling identified adipose-derived palmitoleic acid (16:1n7) as a potent lipid hormone in plasma improving systemic metabolism.
Continue reading: Cell Article | Preview | Press Release